Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with hiv infection and active tuberculosis

Clinical Infectious Diseases

Volumn 49, Issue 9, 2009, Pages 1305-1311

  Boulanger, Catherine ^a   Hollender, Elena ^c   Farrell, Karen ^c   Jean Stambaugh, Jerry ^c   Maasen, Diane ^b   Ashkin, David ^c   Symes, Stephen ^a   Espinoza, Luis A ^a   Rivero, Rafael O ^e   Graham, Jenny J ^f   Peloquin, Charles A ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

^c A G Holley State Hospital   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

^e ABBOTT LABORATORIES   (United States)

^f DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETHAMBUTOL; ISONIAZID; LOPINAVIR PLUS RITONAVIR; PYRAZINAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIFABUTIN; RIFAMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TUBERCULOSIS; TUBERCULOUS MENINGITIS; UVEITIS;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTIVIRAL AGENTS; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; RIFABUTIN; RITONAVIR; TUBERCULOSIS;

EID: 72849124759     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/606056     Document Type: Article

References (20)

1. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Disease Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
2. Burman WJ, Gallicano K, Peloquin CA. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibiotics. Clin Pharmacokinet 2001; 40:327-41.
3. Struble KA, Piscitelli SC. Drug interactions with antiretrovirals for HIV infection. In: Piscitelli SC, Rodvold KA, eds. Drug interactions in infectious diseases. 2nd ed. Totowa, NJ: Humana Press, 2006:101-36.
4. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentration associated with outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Tuberculosis Trials Consortium. Am J Respir Crit Care Med 2003; 167:1341-7.
5. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Tuberculosis Trials Consortium. Clin Infect Dis 2005; 40:1481-91.
6. la Porte CJL, Back DJ, Blaschke T, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther 2006; 3:4-14.
7. Abbott Pharmaceuticals. Kaletra product monograph. Available at: http://www.abbott.ca/static/content/document/Kaletra-PM-13JUL09.pdf. Accessed 24 September 2009.
8. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169-83.
9. Gatti G, Papa P, Torre D, et al. Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998; 42:2017-23.
10. Dodge WF, Jelliffe RW, Zwischenberger JB, Bellanger RA, Hokanson JA, Snodgrass WR. Population pharmacokinetic models: effect of explicit versus assumed constant plasma concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit 1994; 16:552-9.
11. Dodge WF, Jelliffe RW, Zwischenberger JB, Bellanger RA, Hokanson JA, Snodgrass WR. Population pharmacokinetic models: effect of explicit versus assumed constant plasma concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit 1994; 16:552-9.
12. Bustad A, Terziivanov D, Leary R, Port R, Schumitzky A, Jelliffe R. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 2006; 45:365-83.
13. Peloquin CA, Vernon A. Antimycobacterial agents: rifamycins for mycobacterial infections. In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, eds. Antimicrobial chemotherapy and vaccines. 2nd ed. Vol 2 (antimicrobial agents). Pittsburgh, PA: Esun Technologies, 2005: 383-402.
14. Ungheri D, Franceschi G, Della Bruna C. Main human urinary metabolites of the spiropiperidyl rifamycin LM 427: isolation and biological properties. Recent advances in chemotherapy. Antimicrobial section. Proceedings of the 14th International Congress of Chemotherapy (Kyoto). Toyko: University of Toyko Press, 1985:1917-8.
15. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47:2118-24.
16. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51:3781-8.
17. Skinner MH, Hsieh M, Torseth J, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 1989; 33:1237-41.
18. Peloquin CA, Jaresko GS, Yong CL, Keung ACF, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997; 41:2670-9.
19. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 1999; 43:568-72.
20. Hafner R, Bethel J, Power M, et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother 1998; 42:631-9.